Current and emerging evidence for immunomodulatory therapy in community-acquired pneumonia

D Wood, RJ José - Annals of Research Hospitals, 2017 - discovery.ucl.ac.uk
Community-acquired pneumonia (CAP) is the most common infectious disease related
cause of death worldwide despite the use of effective antimicrobials. Much of the morbidity …

Adjunctive therapy in community-acquired pneumonia

RG Wunderink, L Mandell - Seminars in respiratory and critical …, 2012 - thieme-connect.com
Despite potent antibiotics, community-acquired pneumonia (CAP) remains the most
common cause of death from infection and the eighth overall leading cause of death in the …

Immunomodulatory adjuvant therapy in severe community-acquired pneumonia

B Morton, SH Pennington… - Expert Review of …, 2014 - Taylor & Francis
Severe pneumonia has a high mortality (38.2%) despite evidence-based therapy. Rising
rates of antimicrobial resistance increase the urgency to develop new treatment strategies …

Role of the inflammatory response in community-acquired pneumonia: Clinical implications

A Rombauts, G Abelenda-Alonso… - Expert Review of Anti …, 2022 - Taylor & Francis
Introduction Despite adequate antibiotic coverage, community-acquired pneumonia (CAP)
remains a leading cause of hospitalization and mortality worldwide. It induces both a local …

[HTML][HTML] Relevant cytokines in the management of community-acquired pneumonia

A Rendon, EJ Rendon-Ramirez… - … infectious disease reports, 2016 - Springer
Community-acquired pneumonia (CAP) is the leading cause of infectious death in the world.
Immune dysregulation during acute lung infection plays a role in lung injury and the …

Treatment with anti‐inflammatory drugs in community‐acquired pneumonia

SCA Meijvis, EMW Van de Garde… - Journal of internal …, 2012 - Wiley Online Library
Meijvis SCA, van de Garde EMW, Rijkers GT, Bos WJW (St. Antonius Hospital, Nieuwegein;
Utrecht University, Utrecht; St. Antonius Hospital, Nieuwegein; and Roosevelt Academy …

Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review

VF Corrales-Medina, DM Musher - Journal of Infection, 2011 - Elsevier
Despite the availability of excellent antibiotics, the mortality from community-acquired
pneumonia (CAP) remains substantial. Most deaths occur during the first week of …

[HTML][HTML] Nonantibiotic adjunctive therapies for community-acquired pneumonia (corticosteroids and beyond): where are we with them?

O Sibila, A Rodrigo-Troyano… - Seminars in Respiratory …, 2016 - thieme-connect.com
Community-acquired pneumonia (CAP) is a leading cause of hospitalization, morbidity, and
mortality. Despite advances in antibiotic treatments, mortality among patients with CAP is still …

[HTML][HTML] Advances in the prevention, management, and treatment of community-acquired pneumonia

MW Pletz, T Welte, SR Ott - F1000 medicine reports, 2010 - ncbi.nlm.nih.gov
Despite the availability of powerful antibiotics, community-acquired pneumonia (CAP)
remains one of the leading reasons for morbidity and mortality worldwide, and despite the …

[HTML][HTML] Adjunctive immunomodulation in severe community-acquired pneumonia

J Bradley, S Khurana, R Cavallazzi - Jornal Brasileiro de …, 2023 - SciELO Brasil
Community-acquired pneumonia (CAP) is common, affects economically disadvantaged
people disproportionally, and is one of the leading causes of death in the world. Patients …